Filing Details

Accession Number:
0001209191-22-006369
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-02-02 16:20:02
Reporting Period:
2022-01-31
Accepted Time:
2022-02-02 16:20:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1438533 Travere Therapeutics Inc. TVTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1283303 E Elizabeth Reed C/O Travere Therapeutics, Inc.
3611 Valley Centre Dr., Suite 300
San Diego CA 92130
Svp, Gc & Corporate Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-31 9,840 $0.00 45,138 No 4 A Direct
Common Stock Disposition 2022-01-31 1,350 $27.40 43,788 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee stock option (right to buy) Acquisiton 2022-01-31 39,360 $0.00 39,360 $27.50
Common Stock Performance-based restricted stock units Acquisiton 2022-01-31 9,840 $0.00 9,840 $0.00
Common Stock Performance-based restricted stock units Acquisiton 2022-01-31 8,000 $0.00 8,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
39,360 2032-01-30 No 4 A Direct
9,840 No 5 A Direct
8,000 No 5 A Direct
Footnotes
  1. Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.
  2. The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
  3. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
  4. Each PRSU represents a contingent right to receive one share of the Common Stock of the Issuer.
  5. This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.
  6. This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.